Skip to main content
. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245

FigureĀ 1.

FigureĀ 1

Performance on the different matrices with the ESPOIR patients who initially received methotrexate or leflunomide by ROC curve analysis. Data are area under the ROC curve (95% CIs). AUC, area under the ROC curve; CRP, C reactive protein; ROC, receiver operating characteristic.